• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.

作者信息

Spina E, Ancione M, Di Rosa A E, Meduri M, Caputi A P

机构信息

Institute of Pharmacology, University of Messina, Italy.

出版信息

Eur J Clin Pharmacol. 1992;42(3):347-8. doi: 10.1007/BF00266363.

DOI:10.1007/BF00266363
PMID:1349529
Abstract
摘要

相似文献

1
Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.多态性异喹胍氧化与急性抗精神病药物引起的不良反应。
Eur J Clin Pharmacol. 1992;42(3):347-8. doi: 10.1007/BF00266363.
2
Debrisoquine oxidation phenotype during neuroleptic monotherapy.抗精神病药物单一疗法期间的异喹胍氧化表型
Eur J Clin Pharmacol. 1991;41(5):467-70. doi: 10.1007/BF00626371.
3
Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation.抗精神病药物奋乃静、珠氯噻醇和氟哌啶醇的代谢与多态性异喹胍羟化作用共同分离。
Psychopharmacol Ser. 1993;10:230-7. doi: 10.1007/978-3-642-78010-3_21.
4
Evidence for the polymorphic oxidation of debrisoquine in the Thai population.泰国人群中异喹胍多态性氧化的证据。
Br J Clin Pharmacol. 1990 Feb;29(2):244-7. doi: 10.1111/j.1365-2125.1990.tb03627.x.
5
Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions.
Acta Psychiatr Scand. 1992 Nov;86(5):364-6. doi: 10.1111/j.1600-0447.1992.tb03281.x.
6
Debrisoquine oxidation polymorphism in patients with rheumatoid arthritis.类风湿关节炎患者中异喹胍氧化多态性
Ann Rheum Dis. 1994 Mar;53(3):211. doi: 10.1136/ard.53.3.211.
7
Relevance of polymorphic drug oxidation in the use of neuroleptics in schizophrenia.
Prog Clin Biol Res. 1986;214:303-11.
8
Polymorphic 4-hydroxylation of debrisoquine in a Turkish population.土耳其人群中异喹胍的多态性4-羟化作用
Pharmacogenetics. 1991 Nov;1(2):123-4. doi: 10.1097/00008571-199111000-00013.
9
Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
Cancer Chemother Pharmacol. 1988;22(4):321-4. doi: 10.1007/BF00254239.
10
Polymorphic oxidation of debrisoquine in women with breast cancer.乳腺癌女性中异喹胍的多态性氧化作用。
Oncology. 1991;48(2):107-10. doi: 10.1159/000226906.

引用本文的文献

1
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.药物遗传学与抗精神病药：疗效和副作用预测。
Expert Opin Drug Metab Toxicol. 2011 Jan;7(1):9-37. doi: 10.1517/17425255.2011.532787.
2
Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.细胞色素P450 2D6基因分型：在改善精神疾病治疗效果中的潜在作用。
CNS Drugs. 2009;23(3):181-91. doi: 10.2165/00023210-200923030-00001.
3
Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

本文引用的文献

1
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs.抗精神病药物锥体外系副作用的病理生理学
Psychol Med. 1980 Feb;10(1):55-72. doi: 10.1017/s003329170003960x.
2
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.异喹胍代谢缺陷人类常见遗传缺陷的特征分析。
Nature. 1988 Feb 4;331(6155):442-6. doi: 10.1038/331442a0.
3
Inhibitory effects of neuroleptics on debrisoquine oxidation in man.抗精神病药物对人体中异喹胍氧化的抑制作用。
接受抗精神病药物治疗患者的细胞色素P450表型/基因型分析：对处方开具是否有帮助？
Clin Pharmacokinet. 2002;41(7):453-70. doi: 10.2165/00003088-200241070-00001.
4
Pharmacokinetics of haloperidol: an update.氟哌啶醇的药代动力学：最新进展。
Clin Pharmacokinet. 1999 Dec;37(6):435-56. doi: 10.2165/00003088-199937060-00001.
5
Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.抗精神病药物的代谢、药物遗传学及代谢性药物相互作用
Cell Mol Neurobiol. 1999 Aug;19(4):491-510. doi: 10.1023/a:1006938908284.
6
Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment.细胞色素P450酶与药物代谢——评估的基本概念和方法
Cell Mol Neurobiol. 1999 Jun;19(3):309-23. doi: 10.1023/a:1006993631057.
7
Formation of pyridinium species of haloperidol in human liver and brain.
Psychopharmacology (Berl). 1996 Jun;125(3):214-9. doi: 10.1007/BF02247331.
8
Genetically determined adverse drug reactions involving metabolism.涉及代谢的基因决定的药物不良反应。
Drug Saf. 1993 Jul;9(1):60-77. doi: 10.2165/00002018-199309010-00006.
9
Pharmacokinetics of chlorpromazine and key metabolites.氯丙嗪及其关键代谢物的药代动力学。
Eur J Clin Pharmacol. 1993;45(6):563-9. doi: 10.1007/BF00315316.
10
Assessment of liver metabolic function. Clinical implications.肝脏代谢功能评估。临床意义。
Clin Pharmacokinet. 1994 Sep;27(3):216-48. doi: 10.2165/00003088-199427030-00005.
Br J Clin Pharmacol. 1986 Jul;22(1):89-92.
4
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.
Clin Pharmacol Ther. 1989 Jul;46(1):78-81. doi: 10.1038/clpt.1989.109.
5
Substantial rise in sparteine metabolic ratio during haloperidol treatment.在氟哌啶醇治疗期间，鹰爪豆碱代谢率大幅上升。
Br J Clin Pharmacol. 1989 Feb;27(2):272-5. doi: 10.1111/j.1365-2125.1989.tb05362.x.
6
Clinical significance of the sparteine/debrisoquine oxidation polymorphism.司巴丁/异喹胍氧化多态性的临床意义
Eur J Clin Pharmacol. 1989;36(6):537-47. doi: 10.1007/BF00637732.
7
The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.异喹胍/鹰爪豆碱代谢的遗传多态性——临床方面
Pharmacol Ther. 1990;46(3):377-94. doi: 10.1016/0163-7258(90)90025-w.
8
Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type.在异喹胍型弱代谢者中硫利达嗪慢硫氧化的临床意义。
Eur J Clin Pharmacol. 1990;39(6):613-4. doi: 10.1007/BF00316110.
9
Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
Clin Pharmacol Ther. 1991 Mar;49(3):234-40. doi: 10.1038/clpt.1991.22.
10
Debrisoquine oxidation phenotype during neuroleptic monotherapy.抗精神病药物单一疗法期间的异喹胍氧化表型
Eur J Clin Pharmacol. 1991;41(5):467-70. doi: 10.1007/BF00626371.